The FDA has approved the combination of the BRAF inhibitor Braftovi (encorafenib) and the MEK inhibitor Mektovi (binimetinib) for the treatment of patients with BRAF-mutant unresectable or metastatic melanoma, as detected by an FDA-approved test.
Regulatory
FDA Approves Binimetinib/Encorafenib for BRAF+ Melanoma
The FDA has approved the combination of the BRAF inhibitor encorafenib (Braftovi) and the MEK inhibitor binimetinib (Mektovi)
Dabrafenib/Trametinib Combination Approved in BRAF-Mutant Melanoma
The US Food and Drug Administration (FDA) granted approval to the combination of dabrafenib (Tafinlar, Novartis) and trametinib (Mekinist, Novartis) for the adjuvant treatment of melanoma.
Once Monthly Opdivo Use Approved in EU for Certain Melanoma, Renal Cell Cancer Patients
The European Commission has approved a new dosing schedule for Opdivo(nivolumab), allowing the PD-1 inhibitor to be given every four weeks to patients with advanced melanoma and those with previously treated renal cell carcinoma.